Phio Pharmaceuticals Corp.
PHIOHealthcare|Biotechnology|US
$0.80
+0.00 (+0.16%)
DCF Value
$3.45
Tangible Book / Share
$0.74
Cash / Share
$0.91
Financials
Financial Snapshot
Market Cap
$9.3M
Enterprise Value
-$1.3M
Revenue (TTM)
$0.00
Net Income (TTM)
-$14.7M
Cash & Investments
$10.6M
Net Cash
$10.6M
Free Cash Flow (TTM)
-$12.4M
Operating CF (TTM)
-$12.4M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$10.6M
Quarterly Burn
$3.1M
Monthly Burn
$1.0M
Est. Runway
~3.4 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $12.9M | $3.6M | $14.9M | $6.9M | $14.2M | $24.1M | $11.8M | $8.5M | $5.4M | $21.0M | $10.6M | |
| Operating Cash Flow | -$7.8M | -$9.5M | -$7.5M | -$8.6M | -$8.8M | -$11.9M | -$12.1M | -$10.7M | -$7.1M | -$8.0M | -$12.4M | |
| Free Cash Flow | -$7.8M | -$9.7M | -$7.5M | -$8.7M | -$8.8M | -$11.9M | -$12.3M | -$10.8M | -$7.1M | -$8.0M | -$12.4M | |
| Capital Expenditure | -$4.0K | -$203.0K | -$5.0K | -$72.0K | -$19.0K | -$51.0K | -$121.0K | -$5.0K | -$1.0K | -$12.0K | $0.00 | |
| Financing Cash Flow | $10.2M | $292.0K | $18.8M | $772.0K | $16.1M | $21.7M | -$26.0K | $7.4M | $4.0M | $23.6M | $12.3M |
R&D Spending
R&D (TTM)
$10.4M
R&D Intensity
—
R&D Growth vs Prior
+125.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.0K | $15.0K | $138.0K | $21.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $5.4M | $5.4M | $4.3M | $4.3M | $3.7M | $8.9M | $7.0M | $6.3M | $3.6M | $4.6M | $10.4M | |
| R&D % of Revenue | 28500.0% | 35800.0% | 3134.8% | 20476.2% | — | — | — | — | — | — | — | |
| SG&A | $3.6M | $4.0M | $3.2M | $4.7M | $5.1M | $4.6M | $4.5M | $4.3M | $3.7M | $4.6M | $4.8M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.0K | $15.0K | $138.0K | $21.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $5.4M | $5.4M | $4.3M | $0.00 | $3.7M | $8.9M | $7.0M | $6.3M | $3.6M | $4.6M | $1.5M | |
| Gross Profit | -$5.4M | -$5.4M | -$4.2M | $21.0K | -$3.7M | -$8.9M | -$7.0M | -$6.3M | -$3.6M | -$4.6M | -$1.5M | |
| R&D | $5.4M | $5.4M | $4.3M | $4.3M | $3.7M | $8.9M | $7.0M | $6.3M | $3.6M | $4.6M | $10.4M | |
| SG&A | $3.6M | $4.0M | $3.2M | $4.7M | $5.1M | $4.6M | $4.5M | $4.3M | $3.7M | $4.6M | $4.8M | |
| Operating Income | -$9.0M | -$14.1M | -$7.4M | -$9.0M | -$8.8M | -$13.5M | -$11.5M | -$10.8M | -$7.4M | -$9.2M | -$11.0M | |
| Interest Expense | $0.00 | $1.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$9.0M | -$14.1M | -$7.4M | -$8.9M | -$8.8M | -$13.3M | -$11.5M | -$10.8M | -$7.2M | -$8.7M | -$14.7M | |
| Net Income | -$9.0M | -$12.5M | -$7.4M | -$8.9M | -$8.8M | -$13.3M | -$11.5M | -$10.8M | -$7.2M | -$8.7M | -$14.7M | |
| EPS (Diluted) | -79282.81 | -32801.22 | -6218.35 | -2074.18 | -207.25 | -111.32 | -89.61 | -46.76 | -0.91 | -1.45 | -1.26 | |
| EBITDA | -$9.0M | -$14.0M | -$7.3M | -$8.9M | -$8.7M | -$13.2M | -$11.3M | -$10.6M | -$7.1M | -$8.7M | -$10.6M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.12 | 0.13 | 0.23 | 0.79 | 5.98 | 11.69 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.9M | $3.6M | $14.9M | $6.9M | $14.2M | $24.1M | $11.8M | $8.5M | $5.4M | $21.0M | $10.6M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $13.1M | $3.8M | $15.2M | $7.3M | $15.2M | $24.7M | $12.4M | $9.3M | $5.7M | $21.5M | $11.3M | |
| Total Assets | $13.4M | $4.1M | $15.3M | $8.0M | $15.7M | $25.2M | $12.8M | $9.4M | $5.7M | $21.5M | $11.3M | |
| Total Current Liabilities | $2.5M | $2.3M | $1.7M | $1.9M | $2.2M | $3.1M | $1.9M | $1.6M | $1.0M | $435.0K | $886.0K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $231.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $2.5M | $2.3M | $1.7M | $2.3M | $2.7M | $3.2M | $2.0M | $1.6M | $1.0M | $1.3M | $2.7M | |
| Stockholders' Equity | $10.9M | $1.8M | $13.6M | $5.7M | $13.0M | $21.9M | $10.8M | $7.7M | $4.7M | $20.1M | $8.6M | |
| Retained Earnings | -$66.1M | -$78.6M | -$85.9M | -$94.8M | -$103.6M | -$116.9M | -$128.4M | -$139.2M | -$146.4M | -$155.1M | -$167.4M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.8M | -$9.5M | -$7.5M | -$8.6M | -$8.8M | -$11.9M | -$12.1M | -$10.7M | -$7.1M | -$8.0M | -$12.4M | |
| Capital Expenditure | -$4.0K | -$203.0K | -$5.0K | -$72.0K | -$19.0K | -$51.0K | -$121.0K | -$5.0K | -$1.0K | -$12.0K | $0.00 | |
| Free Cash Flow | -$7.8M | -$9.7M | -$7.5M | -$8.7M | -$8.8M | -$11.9M | -$12.3M | -$10.8M | -$7.1M | -$8.0M | -$12.4M | |
| Investing Cash Flow | $5.3M | -$103.0K | -$5.0K | -$72.0K | -$19.0K | -$51.0K | -$121.0K | -$5.0K | $8.0K | -$12.0K | $3.0K | |
| Financing Cash Flow | $10.2M | $292.0K | $18.8M | $772.0K | $16.1M | $21.7M | -$26.0K | $7.4M | $4.0M | $23.6M | $12.3M | |
| Issuance of Stock | $10.2M | $292.0K | $18.8M | $709.0K | $12.1M | $19.6M | $2.0K | $7.5M | $4.0M | $23.7M | $12.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | -$15.0K | $0.00 | $0.00 | -$11.0K | -$1.0K | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | -$6.0K | $204.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $756.0K | $314.0K | $282.0K | $300.0K | $136.0K | $480.0K | $414.0K | $303.0K | $147.0K | $481.0K | $881.0K | |
| Net Change in Cash | $7.8M | -$9.3M | $11.3M | -$7.9M | $7.3M | $9.8M | -$12.3M | -$3.3M | -$3.1M | $15.6M | -$96.0K |
Dilution Tracker
Shares outstanding grew 14002.6% over 5 years — significant dilution
Shares Outstanding
12M
5-Year Share Growth
+14002.6%
Stock Issuance (TTM)
$12.3M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.12 | 0.13 | 0.23 | 0.79 | 5.98 | 11.69 | |
| Change vs Prior % | — | 236.3% | 211.6% | 260.0% | 895.6% | 179.7% | 6.3% | 83.5% | 240.1% | 659.9% | 95.4% | |
| Stock Issuance | $10.2M | $292.0K | $18.8M | $709.0K | $12.1M | $19.6M | $2.0K | $7.5M | $4.0M | $23.7M | $12.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | -$15.0K | $0.00 | $0.00 | -$11.0K | -$1.0K | $0.00 | $0.00 | |
| Stock Based Comp. | $756.0K | $314.0K | $282.0K | $300.0K | $136.0K | $480.0K | $414.0K | $303.0K | $147.0K | $481.0K | $881.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -28400.0% | -35700.0% | -3034.8% | 100.0% | — | — | — | — | — | — | — | |
| Operating Margin % | -47447.4% | -93746.7% | -5336.2% | -42795.2% | — | — | — | — | — | — | — | |
| Net Margin % | -47336.8% | -83013.3% | -5333.3% | -42419.0% | — | — | — | — | — | — | — | |
| EBITDA Margin % | -47168.4% | -93353.3% | -5277.5% | -42476.2% | — | — | — | — | — | — | — | |
| FCF Margin % | -40863.2% | -64780.0% | -5452.9% | -41509.5% | — | — | — | — | — | — | — | |
| ROE % | -82.9% | -679.3% | -54.2% | -155.0% | -67.6% | -60.6% | -105.9% | -140.1% | -151.4% | -43.2% | -101.5% | |
| ROA % | -67.1% | -303.9% | -48.0% | -110.8% | -55.9% | -52.8% | -89.6% | -115.6% | -124.6% | -40.5% | -129.6% | |
| ROIC % | -82.4% | -678.8% | -54.2% | -143.4% | -64.4% | -60.8% | -104.1% | -139.4% | -156.4% | -43.8% | -105.2% | |
| R&D / Revenue % | 28500.0% | 35800.0% | 3134.8% | 20476.2% | — | — | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -44.1% | -21.1% | 820.0% | -84.8% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 21.7% | 0.8% | 21.8% | 100.5% | -17795.2% | -139.1% | 21.1% | 9.7% | 42.5% | -26.8% | |
| Operating Income | 11.9% | -56.0% | 47.6% | -22.0% | 2.2% | -53.7% | 15.2% | 5.6% | 31.8% | -24.8% | |
| Net Income | 12.0% | -38.4% | 40.9% | -21.0% | 1.3% | -51.1% | 13.6% | 5.7% | 34.0% | -21.7% | |
| EPS (Diluted) | 14.8% | 58.6% | 81.0% | 66.6% | 90.0% | 46.3% | 19.5% | 47.8% | 98.1% | -59.3% | |
| Operating Cash Flow | -6.1% | -22.6% | 21.0% | -15.0% | -1.8% | -34.7% | -2.3% | 11.4% | 33.8% | -12.2% | |
| Free Cash Flow | -5.3% | -25.2% | 22.6% | -15.8% | -1.2% | -35.0% | -2.9% | 12.2% | 33.9% | -12.3% | |
| R&D Expense | -21.8% | -0.8% | -19.4% | -0.6% | -13.6% | 139.1% | -21.1% | -9.7% | -42.5% | 26.8% | |
| SG&A Expense | 8.2% | 10.8% | -20.8% | 48.2% | 7.8% | -8.9% | -3.8% | -3.6% | -12.7% | 22.9% | |
| Total Assets | 20.1% | -69.4% | 273.9% | -47.5% | 95.8% | 59.9% | -49.1% | -26.9% | -38.7% | 274.5% | |
| Book Value / Share | 18.9% | -95.0% | 137.7% | -88.2% | -77.3% | -39.8% | -53.5% | -61.1% | -82.1% | -43.9% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 23.9% | -54.0% | -42.4% | -79.4% | -100.0% | 0.0% | |
| Diluted Shares | 2.7% | 236.3% | 211.6% | 260.0% | 895.6% | 179.7% | 6.3% | 83.5% | 240.1% | 659.9% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High16.81 / 252.48 / 836.37
P/B1.09
10Y Low / Med / High0.17 / 0.47 / 6.84
EV/EBITDA0.12
10Y Low / Med / High0.15 / 0.65 / 1.72
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$3.45
Tangible Book / Share
$0.74
Net Current Assets / Share
$0.74
Graham Net-Net
$0.68
Cash / Share
$0.91
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.54 | -1.01 | -0.32 | -0.49 | -1.40 | -0.97 | -0.45 | -0.15 | -1.98 | -0.72 | -0.64 | |
| P/S Ratio | 252.48 | 836.37 | 16.81 | 206.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.44 | 6.84 | 0.17 | 0.75 | 0.95 | 0.58 | 0.47 | 0.20 | 0.30 | 0.31 | 1.09 | |
| EV/EBITDA | 0.90 | -0.64 | 1.72 | 0.23 | 0.15 | 0.83 | 0.58 | 0.65 | 0.56 | 1.70 | 0.12 | |
| EV/Revenue | -426.78 | 597.63 | -91.01 | -99.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-20.63
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Net Income | -$8.6M | -$3.7M |
| EPS | $-1.45 | $-0.61 |
| # Analysts (EPS) | 2 | 2 |